50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher 50% or greater reduction in seizure frequency ‐ ITT analysis compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: diplopia · people with drug‐resistant focal epilepsy
Rufinamide may leads to higher adverse effects: diplopia compared with placebo (low certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant focal epilepsy
Rufinamide showed no clear difference in seizure freedom compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: dizziness compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effect: fatigue · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: fatigue compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: headache · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: headache compared with placebo (moderate certainty).
1 finding from 1 review
Somnolence · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: somnolence compared with placebo (moderate certainty).
1 finding from 1 review
Nausea · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher adverse effects: nausea compared with placebo (moderate certainty).
1 finding from 1 review
Vomiting · people with drug‐resistant focal epilepsy
Rufinamide may leads to higher adverse effects: vomiting compared with placebo (low certainty).
1 finding from 1 review
Seizure freedom · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
Rufinamide plus ASMs leads to higher number of participants with ≥ 50% reduction in all seizures compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Rufinamide plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Seizure freedom · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of adverse events requiring discontinuation of treatment ‐ not reported · Lennox‐Gastaut syndrome, any age
Rufinamide plus ASMs showed no clear difference in number of participants with treatment‐emergent adverse events… compared with other ASM plus ASMs (low certainty).
1 finding from 1 review